CIK 0001501697 · Non-accelerated filer<br>Smaller reporting company
X4 Pharmaceuticals, Inc
Sign in to watch- Ticker
- XFOR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 273181608
- Phone
- 857-529-8300
- Business address
- 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
- Former names
- Arsanis, Inc.
- Open-market buys, last 90 days
- $11,884
- in 1 filing
- Open-market sales, last 90 days
- $33,658
- in 1 filing
Net −$21,775. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-04 | Taveras Arthur Chief Scientific Officer | Grant or award | +230,645 | 464,946 | ||
| 2024-09-09 | DiBiase Mary Chief Operating Officer | Sale | −2,642 | $0.66 | $2K | 289,110 |
| 2024-06-10 | de Craecker Francoise Director | Grant or award | +45,000 | 96,667 | ||
| 2024-06-10 | Aliski William Director | Grant or award | +45,000 | 96,667 | ||
| 2024-06-10 | MCGIRR DAVID W J Director | Grant or award | +45,000 | 96,667 | ||
| 2024-06-10 | Stewart Murray Director | Grant or award | +45,000 | 191,504 | ||
| 2024-06-10 | Bridger Gary Director | Grant or award | +45,000 | 96,667 | ||
| 2024-06-10 | Woods Keith Director | Grant or award | +45,000 | 135,000 | ||
| 2024-06-10 | Lawton Alison Frances Director | Grant or award | +45,000 | 96,667 | ||
| 2024-06-10 | WYZGA MICHAEL S Director | Grant or award | +45,000 | 121,667 | ||
| 2024-05-17 | Baldry Mark Chief Commercial Officer | Purchase | +21,646 | $0.68 | $15K | 115,769 |
| 2024-03-11 | Taveras Arthur Chief Scientific Officer | Sale | −14,235 | $0.88 | $13K | 234,301 |
| 2024-03-11 | Ragan Paula President and CEO | Sale | −49,678 | $0.88 | $44K | 765,068 |
| 2024-03-11 | Mostafa Adam S. Chief Financial Officer | Sale | −52,500 | $0.88 | $46K | 0 |
| 2024-03-11 | DiBiase Mary Chief Operating Officer | Sale | −15,409 | $0.88 | $14K | 291,752 |
| 2024-02-13 | Arbet-Engels Christophe Chief Medical Officer | Grant or award · Stock Appreciation Right | +180,816 | 180,816 | ||
| 2024-02-13 | Arbet-Engels Christophe Chief Medical Officer | Grant or award · Stock Appreciation Right | +475,831 | 475,831 | ||
| 2024-02-13 | Mostafa Adam S. Chief Financial Officer | Grant or award · Stock Appreciation Right | +523,414 | 523,414 | ||
| 2024-02-13 | DiBiase Mary Chief Operating Officer | Grant or award · Stock Appreciation Right | +428,248 | 428,248 | ||
| 2024-02-13 | Ragan Paula President and CEO | Grant or award · Stock Appreciation Right | +1,189,578 | 1,189,578 |
Page 4 of 6 · 120 trades